Inflammation, cytokines and insulin resistance: A clinical perspective

Archivum Immunologiae et Therapiae Experimentalis

Volumn 61, Issue 2, 2013, Pages 119-125

  Wieser, Verena ^a   Moschen, Alexander R ^a   Tilg, Herbert ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Adipocytokines; Anti cytokine therapies; Innate immunity; Type 2 diabetes

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALICYLIC ACID; SALSALATE; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA;

DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DYSLIPIDEMIA; GASTROINTESTINAL TOXICITY; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INFLAMMATION; INSULIN RESISTANCE; MOLECULAR PATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ADIPOSE TISSUE; ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; CYTOKINES; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY; INFLAMMASOMES; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; LIPID METABOLISM; NF-KAPPA B; OBESITY;

EID: 84879459608     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-012-0210-1     Document Type: Review

References (65)

1. Aguirre V, Uchida T, Yenush L et al (2000) The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem 275:9047-9054 (Pubitemid 30180265)
2. Arkan MC, Hevener AL, Greten FR et al (2005) IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 11:191-198 (Pubitemid 40321355)
3. Barbuio R, Milanski M, Bertolo MB et al (2007) Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet. J Endocrinol 194:539-550 (Pubitemid 47471222)
4. Bernstein LE, Berry J, Kim S et al (2006) Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med 166:902-908
5. Cai D, Yuan M, Frantz DF et al (2005) Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 11:183-190 (Pubitemid 40321354)
6. Carstensen M, Herder C, Kivimaki M et al (2010) Accelerated increase in serum interleukin-1 receptor antagonist starts 6 years before diagnosis of type 2 diabetes: whitehall II prospective cohort study. Diabetes 59:1222-1227
7. Clowes GH Jr, Martin H, Walji S et al (1978) Blood insulin responses to blood glucose levels in high output sepsis and septic shock. Am J Surg 135:577-583 (Pubitemid 8336698)
8. da Silva BS, Bonfa E, de Moraes JC et al (2010) Effects of anti-TNF therapy on glucose metabolism in patients with ankylosing spondylitis, psoriatic arthritis or juvenile idiopathic arthritis. Biologicals 38:567-569
9. Dandona P, Weinstock R, Thusu K et al (1998) Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab 83:2907-2910 (Pubitemid 28493796)
10. Di Gregorio GB, Hensley L, Lu T et al (2004) Lipid and carbohydrate metabolism in mice with a targeted mutation in the IL-6 gene: absence of development of age-related obesity. Am J Physiol Endocrinol Metab 287:E182-E187 (Pubitemid 38856299)
11. Dinarello CA (2011) Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117:3720-3732
12. Dominguez H, Storgaard H, Rask-Madsen C et al (2005) Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res 42:517-525 (Pubitemid 41527607)
13. Donath MY, Shoelson SE (2011) Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 11:98-107
14. Ebstein W (1876) Zur therapie des diabetes mellitus, insbesondere über die anwendeng der salicylauren natron bei demselben. Berliner Klinische Wochenschrift 13:337-340
15. Ehses JA, Lacraz G, Giroix MH et al (2009) IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc Natl Acad Sci USA 106:13998-14003
16. Ellingsgaard H, Hauselmann I, Schuler B et al (2011) Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med 17:1481-1489
17. Ferraz-Amaro I, Arce-Franco M, Muniz J et al (2011) Systemic blockade of TNF-α does not improve insulin resistance in humans. Horm Metab Res 43:801-808
18. Fu S, Watkins SM, Hotamisligil GS (2012) The role of endoplasmic reticulum in hepatic lipid homeostasis and stress signaling. Cell Metab 15:623-634
19. Glass CK, Olefsky JM (2012) Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab 15:635-645
20. Goldfine AB, Fonseca V, Jablonski KA et al (2010) The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med 152:346-357
21. Goldfine AB, Buck S, Jablonski KA et al (2012) Targeting inflammation using SALsalate in patients with type 2 diabetes: effects on flow-mediated dilatation (TINSAL-FMD). Diabetes 61(Suppl 1):A303
22. Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C et al (2006) Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 24:83-86
23. Hak AE, Stehouwer CD, Bots ML et al (1999) Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol 19:1986-1991 (Pubitemid 29379933)
24. He J, Usui I, Ishizuka K et al (2006) Interleukin-1 alpha inhibits insulin signaling with phosphorylating insulin receptor substrate-1 on serine residues in 3T3-L1 adipocytes. Mol Endocrinol 20:114-124 (Pubitemid 43011674)
25. Hingorani AD, Casas JP (2012) The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 379:1214-1224
26. Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259:87-91 (Pubitemid 23036092)
27. Hotamisligil GS, Peraldi P, Budavari A et al (1996) IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271:665-668 (Pubitemid 26052915)
28. Hundal RS, Petersen KF, Mayerson AB et al (2002) Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 109:1321-1326 (Pubitemid 34546896)
29. Kamari Y, Shaish A, Vax E et al (2011) Lack of interleukin-1α or interleukin-1β inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice. J Hepatol 55:1086-1094
30. Kanda H, Tateya S, Tamori Y et al (2006) MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 116:1494-1505
31. Kern PA, Saghizadeh M, Ong JM et al (1995) The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 95:2111-2119
32. Klover PJ, Clementi AH, Mooney RA (2005) Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology 146:3417-3427 (Pubitemid 41058114)
33. Kopp HP, Kopp CW, Festa A et al (2003) Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol 23:1042-1047 (Pubitemid 36713558)
34. Koutroubakis IE, Oustamanolakis P, Malliaraki N et al (2009) Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 21:283-288
35. Lagathu C, Yvan-Charvet L, Bastard JP et al (2006) Long-term treatment with interleukin-1 beta induces insulin resistance in murine and human adipocytes. Diabetologia 49:2162-2173 (Pubitemid 44168485)
36. Larsen CM, Faulenbach M, Vaag A et al (2007) Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356:1517-1526 (Pubitemid 46588416)
37. Larsen CM, Faulenbach M, Vaag A et al (2009) Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 32:1663-1668
38. Li Z, Yang S, Lin H et al (2003) Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 37:343-350 (Pubitemid 36152533)
39. Mehta NN, McGillicuddy FC, Anderson PD et al (2010) Experimental endotoxemia induces adipose inflammation and insulin resistance in humans. Diabetes 59:172-181
40. Meier CA, Bobbioni E, Gabay C et al (2002) IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin? J Clin Endocrinol Metab 87:1184-1188 (Pubitemid 36121085)
41. Miura K, Kodama Y, Inokuchi S et al (2010) Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology 139(323-334):e7
42. Moschen AR, Molnar C, Geiger S et al (2010) Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor alpha expression. Gut 59:1259-1264
43. Moschen AR, Molnar C, Enrich B et al (2011) Adipose and liver expression of interleukin (IL)-1 family members in morbid obesity and effects of weight loss. Mol Med 17:840-845
44. Nold MF, Nold-Petry CA, Zepp JA et al (2010) IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol 11:1014-1022
45. Ofei F, Hurel S, Newkirk J et al (1996) Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 45:881-885 (Pubitemid 26225502)
46. Ogata A, Morishima A, Hirano T et al (2011) Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab. Ann Rheum Dis 70:1164-1165
47. Owyang AM, Maedler K, Gross L et al (2010) XOMA 052, an anti-IL-1beta monoclonal antibody, improves glucose control and beta-cell function in the diet-induced obesity mouse model. Endocrinology 151:2515-2527
48. Paquot N, Castillo MJ, Lefebvre PJ et al (2000) No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. J Clin Endocrinol Metab 85:1316-1319 (Pubitemid 32269392)
49. Pihlajamaki J, Kuulasmaa T, Kaminska D et al (2012) Serum interleukin 1 receptor antagonist as an independent marker of non-alcoholic steatohepatitis in humans. J Hepatol 56:663-670
50. Pradhan AD, Cook NR, Manson JE et al (2009) A randomized trial of low-dose aspirin in the prevention of clinical type 2 diabetes in women. Diabetes Care 32:3-8
51. Raymond RM, Harkema JM, Emerson TE Jr (1981) In vivo skeletal muscle insulin resistance during E. coli endotoxin shock in the dog. Circ Shock 8:425-433 (Pubitemid 11035463)
52. Ridker PM, Thuren T, Zalewski A et al (2011) Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 162:597-605
53. Rosenvinge A, Krogh-Madsen R, Baslund B et al (2007) Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNFalpha therapy. Scand J Rheumatol 36:91-96 (Pubitemid 46685768)
54. Samuel VT, Shulman GI (2012) Mechanisms for insulin resistance: common threads and missing links. Cell 148:852-871
55. Schultz O, Oberhauser F, Saech J et al (2010) Effects of inhibition of interleukin-6 signaling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS ONE 5:e14328
56. Stienstra R, Tack CJ, Kanneganti TD et al (2012) The inflammasome puts obesity in the danger zone. Cell Metab 15:10-18
57. Svenson KL, Lundqvist G, Wide L et al (1987) Impaired glucose handling in active rheumatoid arthritis: relationship to the secretion of insulin and counter-regulatory hormones. Metabolism 36:940-943 (Pubitemid 17160510)
58. Uysal KT, Wiesbrock SM, Marino MW et al (1997) Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 389:610-614 (Pubitemid 27446179)
59. Wallenius V, Wallenius K, Ahren B et al (2002) Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 8:75-79 (Pubitemid 34101732)
60. Wascher TC, Lindeman JH, Sourij H et al (2011) Chronic TNF-α neutralization does not improve insulin resistance or endothelial function in "healthy" men with metabolic syndrome. Mol Med 17:189-193
61. Weisberg SP, McCann D, Desai M et al (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796-1808 (Pubitemid 38063703)
62. Weisberg SP, Hunter D, Huber R et al (2006) CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 116:115-124 (Pubitemid 43121796)
63. Yin MJ, Yamamoto Y, Gaynor RB (1998) The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396:77-80 (Pubitemid 28520452)
64. Yuan M, Konstantopoulos N, Lee J et al (2001) Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 293:1673-1677 (Pubitemid 32807849)
65. Yudkin JS, Stehouwer CD, Emeis JJ et al (1999) C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19:972-978 (Pubitemid 29177345)